Novel Agents And Combinations

Improvements in our understanding of the pathobiol-ogy of MDS will help to generate new therapeutic approaches. As new agents are developed, some will be appropriate for low-risk patients, and given the

Clinical trials of hypomethylating agents in MDS

Reference

Phase of trial

Number of patients

Dose

Response rate

Comments

0 0

Post a comment